GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer’s disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood biomarkers, recent studies have identified other reliable candidates that can serve as measurable indicators of pathologic...
Main Authors: | Ka Young Kim, Ki Young Shin, Keun-A Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/9/1309 |
Similar Items
-
Whether Serum Glial Fibrillary Acidic Protein (GFAP) Can Be Used as a Diagnostic Biomarker in Patients With Glioblastoma?
by: Charandeep Singh Gandhoke, et al.
Published: (2020-01-01) -
Relapsing Autoimmune GFAP Astrocytopathy: Case Report
by: Ekaterina O. Chekanova, et al.
Published: (2023-12-01) -
A case of glial fibrillary acidotic protein (GFAP) meningoencephalitis with rheumatoid arthritis
by: Mehri Salari, et al.
Published: (2023-03-01) -
Serum GFAP as a biomarker for disease severity in multiple sclerosis
by: A. Abdelhak, et al.
Published: (2018-10-01) -
Case report: Headache as the sole neurological symptom in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
by: Eslam Shosha, et al.
Published: (2024-04-01)